Ribomic (TSE:4591) Ending Cash Position: 円1,927.18 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4591 Ribomic Inc TSE:4591
25 GF Score
Price 円75.00
! 3 Warning Signs
View Full Analysis

What is Ribomic Ending Cash Position?

Ribomic TSE:4591 25 Ending Cash Position is 円1,927.18 Mil as of Mar. 2026. GuruFocus rates TSE:4591 with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

Ribomic's Ending Cash Position for the quarter that ended in Mar. 2026 was 円1,927.18 Mil.

Ribomic's quarterly Ending Cash Position increased from Mar. 2025 (円1,837.12 Mil) to Sep. 2025 (円1,921.73 Mil) and increased from Sep. 2025 (円1,921.73 Mil) to Mar. 2026 (円1,927.18 Mil).

Ribomic's annual Ending Cash Position declined from Mar. 2024 (円2,099.74 Mil) to Mar. 2025 (円1,837.12 Mil) but then increased from Mar. 2025 (円1,837.12 Mil) to Mar. 2026 (円1,927.18 Mil).

Ribomic Ending Cash Position Related Terms

Ribomic Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Ribomic's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ribomic Ending Cash Position Chart

Ribomic Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,901.80 2,825.18 2,099.74 1,837.12 1,927.18

Ribomic Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.34 1,763.64 1,837.12 1,921.73 1,927.18
TSE:4591
25GF Score
Ribomic Inc TSE:4591
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ribomic Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Ribomic's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1837.124+90.056
=1,927.18

Ribomic's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1921.728+5.4519999999999
=1,927.18

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of 円1,927.18 Mil mean?
Ribomic (TSE:4591) has a Ending Cash Position of 円1,927.18 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ribomic and its competitors.
Is Ribomic's Ending Cash Position too high?
Ribomic's current Ending Cash Position is 円1,927.18 Mil. Overall, Ribomic has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Ribomic's Ending Cash Position compare to VRTX and REGN?
Ribomic's Ending Cash Position of 円1,927.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ribomic and its competitors. Ribomic's current Ending Cash Position is 円1,927.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ribomic stock overvalued right now?
Ribomic (TSE:4591) has a current Ending Cash Position of 円1,927.18 Mil. The current Ending Cash Position is 円1,927.18 Mil. Ribomic's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Ribomic (TSE:4591), the current Ending Cash Position is 円1,927.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ribomic Business Description

Address 3-16-13 Usui Building, Shirokanedai, Minato-ku, Tokyo, JPN, 108-0071
Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.
25GF Score

Get the complete analysis for TSE:4591

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円75.00
Price